ISLAMABAD (Kashmir English): A new experimental cancer vaccine has shown promising results in a major clinical trial, reducing the risk of death by 41% among patients suffering from acute myeloid leukemia (AML), an aggressive form of blood cancer.
The vaccine, known as galinpepimut-S (GPS), was tested in a Phase 3 REGAL clinical trial involving 126 patients whose leukemia had returned after previous treatment.
According to results announced by biotechnology company Sellas Life Sciences on November 17, patients receiving the vaccine had a median overall survival of 24 months, compared with 14.7 months among those receiving alternative treatments.
The vaccine works by stimulating the immune system to recognise and attack cancer cells carrying a protein called Wilms’ Tumour 1 (WT1). It is designed to target remaining leukemia cells after chemotherapy and potentially prevent the disease from returning.
Researchers reported that the treatment was generally well tolerated, with injection-site reactions among the most common side effects.
Sellas Life Sciences plans to pursue regulatory approval from the US Food and Drug Administration (FDA), with a Biologics License Application expected in the first half of 2027.
However, the vaccine remains experimental and has not yet received FDA approval.




